Mayo, GE, Deloitte join to expand personalized medicine

Vineti, a cell and gene therapy platform, and Deloitte, an audit and consulting firm, are collaborating to bring personalized medicine solutions to life sciences companies, healthcare providers and patients.

Vineti, which was co-founded by GE and Rochester, Minn.-based Mayo Clinic, offers healthcare providers a cloud-based software platform to streamline the process to connect patients with individualized cell and gene therapies, primarily by managing and centralizing data from providers, pharmaceutical companies and drug manufacturers.

Under the partnership with Deloitte, Vineti will integrate its platform with Deloitte's ConvergeHEALTH Patient Connect, a patient engagement tool that connects patients and providers with pharmaceutical and medical device vendors.

Together, Vineti and Deloitte say the integration will help life sciences companies connect with healthcare providers and overcome supply chain and patient engagement challenges. By addressing these barriers, the companies say their integrated products will allow life sciences companies and healthcare providers to expand patient access to individualized cellular therapies.

"The advancement of truly personalized therapies reinforces not just the belief but the practice that the patient is at the center of therapeutic production, delivery and support," Amy DuRoss, CEO and co-founder of Vineti, said in a news release announcing the collaboration.

More articles on data analytics & precision medicine:
Who do patients want to share health data with?
Analytics startups cinched $911M in funding in the first half of 2018
Data governance: 4 considerations for hospitals to balance

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.